UpdatesPress Release

Emcure's Poviztra® (semaglutide) received CDSCO approval for MASH treatment, expanding its market into a significant unmet medical need.

Emcure Pharmaceuticals Limited logo
Emcure Pharmaceuticals LimitedEMCURE · Filed with the exchange

This makes it the first GLP-1 receptor agonist approved for this progressive liver disease in India, bolstering Emcure's metabolic portfolio.

Read the original filing(PDF)

No comments yet. Be the first.

More from Emcure Pharmaceuticals Limited

All announcements